Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.4K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.4K
Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Motivational interviewing improves exclusive breastfeeding in an Australian randomised controlled trial.

Acta paediatrica (Oslo, Norway : 1992)·2013
Same author

Cardiologists are more willing to prescribe β-blockers than respiratory physicians: an Australasian clinical scenario survey.

Internal medicine journal·2012
Same author

Apoptosis-regulatory factors as potential drug targets in the epithelium of normal and inflamed airways.

Current molecular pharmacology·2009
Same author

Chlorofluorocarbon-free inhalation devices in asthma: are there clinical implications?

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.

Leukemia·2006
Same author

Zinc and its specific transporters as potential targets in airway disease.

Current drug targets·2006
Same journal

Corrigendum.

The Journal of allergy and clinical immunology·2026
Same journal

Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.

The Journal of allergy and clinical immunology·2026
Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026
Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026
Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 5, 2010

34.4K

Combination bronchodilator therapy in asthma.

R E Ruffin, E McIntyre, A J Crockett

    The Journal of Allergy and Clinical Immunology
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Combination therapy with ipratropium bromide and fenoterol offers superior short-term bronchodilator effects for asthma patients. This inhaled bronchodilator approach may provide significant therapeutic gains.

    More Related Videos

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
    07:10

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

    Published on: May 20, 2019

    13.5K
    A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
    05:56

    A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

    Published on: May 12, 2023

    6.6K

    Related Experiment Videos

    Last Updated: May 5, 2026

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
    14:39

    Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

    Published on: November 5, 2010

    34.4K
    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
    07:10

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

    Published on: May 20, 2019

    13.5K
    A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
    05:56

    A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

    Published on: May 12, 2023

    6.6K

    Area of Science:

    • Pharmacology
    • Respiratory Medicine
    • Clinical Trials

    Background:

    • Asthma management relies on bronchodilators.
    • Inhaled anticholinergic and sympathomimetic agents are key treatments.
    • Optimizing combination therapy requires further investigation.

    Purpose of the Study:

    • To compare short-term bronchodilator effects of ipratropium bromide and fenoterol.
    • To evaluate these agents alone and in combination.
    • To determine optimal dosing for combined inhaled bronchodilator therapy.

    Main Methods:

    • Double-blind, placebo-controlled, crossover study design.
    • Involved 18 patients with asthma.
    • Assessed bronchodilator effects of various drug combinations.

    Main Results:

    • The combination of 60 mcg ipratropium bromide and 200 mcg fenoterol showed enhanced bronchodilation.
    • This combination was more effective than lower doses or monotherapy.
    • Significant short-term bronchodilator gains were observed.

    Conclusions:

    • Combination inhaled bronchodilator therapy can yield significant benefits.
    • Higher doses of ipratropium bromide and fenoterol combination are effective.
    • Further research may refine combination inhaled bronchodilator strategies.